Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07000292 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

Study acronym: MSC303
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 11, 2025 (before its estimated May 20, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint revised
    • Eligibility criteria expanded, about 13 words
    • Study description expanded, about 9 words
    • Site contact updated
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.
Trial Details
NCT Number NCT07000292
Lead Sponsor Shanghai Changzheng Hospital
Conditions
(from sponsor)		 Lupus Nephritis (LN), ANCA-Associated Glomerulonephritis
Related terms Lupus Nephritis
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov